Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

Looking at options history for Merck & Co MRK we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish ...

The initiatives to improve healthcare access — including Ayushman Bharat, which provides financial protection and better ...

Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in space history don't miss ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best magic formula stocks for 2025. The Magic Formula, as defined by Joel Greenblatt in his ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...